NCT03424486View on ClinicalTrials.gov

Prevalence and Impact of Depression and Anxiety in Cystic Fibrosis

CompletedOBSERVATIONAL
Enrollment

108

Participants

Timeline

Start Date

November 23, 2017

Primary Completion Date

July 11, 2019

Study Completion Date

July 11, 2019

Conditions
Cystic Fibrosis
Interventions
OTHER

Questionnaires

Evaluation of the prevalence of anxiety, depression and quality of life

Trial Locations (8)

14000

CRCM - Service de Pédiatrie - Pôle FEH - CHU Caen), Caen

25000

CRCM Enfants - Service de Pneumologie - Hôpital Jean Minjoz, Besançon

33000

CRCM Pédiatrique - Hôpital des Enfants, Bordeaux

37000

CRCM / Service de Pédiatrie _ Hôpital de Clocheville - CHRU de Tours, Tours

51100

CRCM - Service de Pédiatrie A - American Memorial Hospital, Reims

54511

CRCM / Service de Médecine Infantile - Hôpital d'Enfants - CHRU Nancy, Nancy

75015

Department of Pneumology - CRCM- Necker - Enfants malades Hospital (AP-HP) -, Paris

80000

CRCM - Service de Pneumologie Pédiatrique - CHU Amiens - Site Sud, Amiens

All Listed Sponsors
collaborator

Vaincre la Mucoviscidose

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03424486 - Prevalence and Impact of Depression and Anxiety in Cystic Fibrosis | Biotech Hunter | Biotech Hunter